JNJ
Johnson & Johnson
NYSE · Healthcare · Drug Manufacturers - General · US
$275.42
−1.08%Sep 1, 2026, 21:45 UTC
Johnson & Johnson shares rose 2.01% to $271.19 in the latest session, outperforming the S&P 500's 0.71% decline.
Source:Aug 27, 2026, 08:33 UTC
Johnson & Johnson announced that its IL-23 receptor antagonist oral peptide drug Ateya (ecopipitant hydrochloride tablets) received approval from China's National Medical Products Administration for treating moderate-to-severe plaque psoriasis in adults and children aged 12 and above weighing at least 40 kg.
Source:Aug 25, 2026, 00:00 UTC
Parabilis Medicines, Inc. appointed Craig Tendler, M.D., as a director, effective August 22, 2026, and granted him a stock option to purchase 20,294 shares of common stock at an exercise price of $39.36 per share.
Aug 24, 2026, 22:33 UTC
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's drug to treat a rare blood disorder, announced by the company on Monday.
Aug 24, 2026, 16:20 UTC
A Louisiana jury awarded a $10 million verdict in a mesothelioma case against Johnson & Johnson, brought by the family of Lynne Roy over talc exposure.
Source:Aug 22, 2026, 04:15 UTC
A US judge in Virginia ruled in favor of three researchers in a defamation lawsuit filed by Johnson & Johnson over a 2020 scientific article linking talc to cancer.
Source:Aug 21, 2026, 16:46 UTC
Johnson & Johnson received FDA 510(k) clearance for the MONARCH QUEST 3 update, adding AI-powered planning, navigation, and imaging upgrades for robotic bronchoscopy.
Source:Aug 20, 2026, 07:24 UTC
Benjamin Edwards Inc. increased its stake in Johnson & Johnson by 21.8% during the second quarter of 2026, purchasing an additional 28,700 shares, according to its Form 13F filing.
Source:Aug 19, 2026, 19:38 UTC
Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.
Source:Aug 13, 2026, 23:59 UTC
Johnson & Johnson donated $300,000 to Rutgers School of Nursing-Camden to modernize its nursing simulation lab and fund scholarships, with a dedication ceremony held on August 12.
Source:Aug 13, 2026, 13:55 UTC
Johnson Pharmaceutical announced its first-half 2026 financial results, with revenue of NT$293 million and net profit attributable to parent of NT$76.75 million, up 87.76% year-on-year, driven by rising demand for chronic disease and CNS drugs.
Source:Aug 13, 2026, 12:00 UTC
MeiraGTx completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) from Johnson & Johnson for $25 million.
Source:Aug 13, 2026, 07:35 UTC
Ballast Inc. increased its stake in Johnson & Johnson by 9.0% during the quarter, acquiring an additional 2,088 shares, according to its SEC disclosure.
Source:Aug 12, 2026, 12:13 UTC
Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., to its Board of Directors on August 12, 2026.
Source:Aug 10, 2026, 05:32 UTC
Kaken Pharmaceutical reported first-quarter (April-June) operating profit of 10.902 billion yen, a significant increase from 14 million yen a year earlier, boosted by a $70 million milestone payment from Johnson & Johnson under a licensing agreement.
Source:Aug 9, 2026, 06:00 UTC
Johnson & Johnson offered $5.5 billion to settle over 70,000 outstanding talc-related cancer lawsuits.
Source:Aug 4, 2026, 19:23 UTC
Johnson & Johnson spent $25 billion on share repurchases over the past five years.
Source:Aug 4, 2026, 19:23 UTC
Johnson & Johnson paid $60 billion in dividends to shareholders over the past five years.
Source:Aug 4, 2026, 12:45 UTC
Johnson & Johnson announced that Tom Kavanagh will succeed Jennifer Taubert as Executive Vice President and Worldwide Chairman of the Innovative Medicine segment.
Aug 3, 2026, 23:59 UTC
The trial of former New Mexico state lawmaker Sheryl Williams Stapleton began in U.S. District Court in Albuquerque, where she faces 37 criminal counts including conspiracy, bribery, money laundering, and mail fraud for allegedly approving about $3.2 million in payments to Robotics Management Learning Systems and receiving about $1.1 million in kickbacks.
Aug 3, 2026, 16:21 UTC
Johnson & Johnson reported strong Q2 2026 oncology performance, with sales boosted by Darzalex, Erleada, and newer cancer drugs.
Source:Aug 3, 2026, 00:00 UTC
Lipocine Inc. appointed Michael J. Grissinger as a director, effective August 3, 2026, with an initial stock option grant to purchase 2,000 shares of common stock.
Source:Jul 31, 2026, 18:19 UTC
Johnson & Johnson announced two biotech acquisitions totaling $3.5 billion to expand its oncology pipeline.
Source:Jul 30, 2026, 12:30 UTC
Johnson & Johnson announced that the U.S. FDA granted Priority Review to its supplemental Biologics License Application for subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma.
Source:Jul 29, 2026, 21:46 UTC
Sail Biomedicines announced a strategic collaboration with Johnson & Johnson to develop In Vivo CAR-T therapies for immune-mediated diseases.
Source:Jul 29, 2026, 21:42 UTC
Johnson & Johnson completed the acquisition of Firefly Bio to advance next-generation oncology innovation.
Jul 29, 2026, 21:31 UTC
Johnson & Johnson entered into a strategic agreement with Sail Biomedicines, obtaining an exclusive option to acquire the company for $2.58 billion and concurrently making an equity investment, with an initial total payment of $785 million.
Jul 25, 2026, 14:00 UTC
Johnson & Johnson MedTech unveiled its Ottava surgical robot after receiving FDA de novo authorization.
Source:Jul 22, 2026, 11:00 UTC
The U.S. Food and Drug Administration granted De Novo marketing authorization for Johnson & Johnson's OTTAVA Robotic Surgical System.
Jul 15, 2026, 16:09 UTC
Johnson & Johnson reported progress toward a table-integrated robotic surgical system.
Source:Jul 15, 2026, 10:25 UTC
Johnson & Johnson's Board of Directors declared a quarterly cash dividend of $1.34 per share for the third quarter of 2026, payable on September 8, 2026 to shareholders of record on August 25, 2026.
Source:
Page 1Next →